vs
Side-by-side financial comparison of Charles River Laboratories (CRL) and Polestar Automotive Holding UK PLC (PSNY). Click either name above to swap in a different company.
Charles River Laboratories is the larger business by last-quarter revenue ($994.2M vs $685.2M, roughly 1.5× Polestar Automotive Holding UK PLC). Charles River Laboratories runs the higher net margin — -27.8% vs -44.4%, a 16.6% gap on every dollar of revenue. Charles River Laboratories produced more free cash flow last quarter ($58.6M vs $-709.7M).
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.
Polestar Automotive Holding UK PLC, or simply Polestar, is a Swedish automotive manufacturer that produces electric cars. Principally owned by Li Shufu's PSD Investment, Geely Holding and Volvo Cars, the company is headquartered in Torslanda, outside Gothenburg, Sweden. With an "asset-light" approach in development and manufacturing, Polestar does not have its own manufacturing facility; instead it produces cars in facilities controlled by Volvo or Geely in several countries, including China,...
CRL vs PSNY — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2023
| Metric | | |
|---|---|---|
| Revenue | $994.2M | $685.2M |
| Net Profit | $-276.6M | $-304.1M |
| Gross Margin | — | -0.1% |
| Operating Margin | -28.5% | -72.6% |
| Net Margin | -27.8% | -44.4% |
| Revenue YoY | -0.8% | — |
| Net Profit YoY | -28.9% | — |
| EPS (diluted) | $-5.57 | $-0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $994.2M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $984.2M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $-276.6M | — | ||
| Q3 25 | $54.4M | — | ||
| Q2 25 | $52.3M | — | ||
| Q1 25 | $25.5M | — | ||
| Q4 24 | $-214.5M | — | ||
| Q3 24 | $69.7M | — | ||
| Q2 24 | $94.1M | — | ||
| Q1 24 | $73.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 34.6% | — | ||
| Q2 24 | 34.5% | — | ||
| Q1 24 | 34.1% | — |
| Q4 25 | -28.5% | — | ||
| Q3 25 | 13.3% | — | ||
| Q2 25 | 9.7% | — | ||
| Q1 25 | 7.6% | — | ||
| Q4 24 | -16.7% | — | ||
| Q3 24 | 11.6% | — | ||
| Q2 24 | 14.8% | — | ||
| Q1 24 | 12.5% | — |
| Q4 25 | -27.8% | — | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -21.4% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | 9.2% | — | ||
| Q1 24 | 7.2% | — |
| Q4 25 | $-5.57 | — | ||
| Q3 25 | $1.10 | — | ||
| Q2 25 | $1.06 | — | ||
| Q1 25 | $0.50 | — | ||
| Q4 24 | $-4.17 | — | ||
| Q3 24 | $1.33 | — | ||
| Q2 24 | $1.74 | — | ||
| Q1 24 | $1.30 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $213.8M | $1.1B |
| Total DebtLower is stronger | $2.1B | $1.6B |
| Stockholders' EquityBook value | $3.2B | $-456.3M |
| Total Assets | $7.1B | $4.3B |
| Debt / EquityLower = less leverage | 0.68× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $213.8M | — | ||
| Q3 25 | $207.1M | — | ||
| Q2 25 | $182.8M | — | ||
| Q1 25 | $229.4M | — | ||
| Q4 24 | $194.6M | — | ||
| Q3 24 | $210.2M | — | ||
| Q2 24 | $179.2M | — | ||
| Q1 24 | $327.0M | — |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.2B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.8B | — | ||
| Q2 24 | $3.7B | — | ||
| Q1 24 | $3.6B | — |
| Q4 25 | $7.1B | — | ||
| Q3 25 | $7.5B | — | ||
| Q2 25 | $7.6B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.5B | — | ||
| Q3 24 | $8.0B | — | ||
| Q2 24 | $7.9B | — | ||
| Q1 24 | $8.2B | — |
| Q4 25 | 0.68× | — | ||
| Q3 25 | 0.64× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 0.65× | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.73× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.5M | $-666.7M |
| Free Cash FlowOCF − Capex | $58.6M | $-709.7M |
| FCF MarginFCF / Revenue | 5.9% | -103.6% |
| Capex IntensityCapex / Revenue | 8.9% | 6.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $518.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $147.5M | — | ||
| Q3 25 | $213.8M | — | ||
| Q2 25 | $204.6M | — | ||
| Q1 25 | $171.7M | — | ||
| Q4 24 | $159.4M | — | ||
| Q3 24 | $251.8M | — | ||
| Q2 24 | $193.5M | — | ||
| Q1 24 | $129.9M | — |
| Q4 25 | $58.6M | — | ||
| Q3 25 | $178.2M | — | ||
| Q2 25 | $169.3M | — | ||
| Q1 25 | $112.4M | — | ||
| Q4 24 | $83.7M | — | ||
| Q3 24 | $213.1M | — | ||
| Q2 24 | $154.0M | — | ||
| Q1 24 | $50.7M | — |
| Q4 25 | 5.9% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 16.4% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 8.4% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 15.0% | — | ||
| Q1 24 | 5.0% | — |
| Q4 25 | 8.9% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 7.5% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 7.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 3.93× | — | ||
| Q2 25 | 3.91× | — | ||
| Q1 25 | 6.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.61× | — | ||
| Q2 24 | 2.06× | — | ||
| Q1 24 | 1.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
PSNY
Segment breakdown not available.
